We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Study Explains Link between Genetic Variation and Vaccine Specificity and Persistence

By LabMedica International staff writers
Posted on 24 Jun 2019
To better explain how genetic variation affects antibody production and specificity following immunization, researchers conducted a GWAS (genome-wide association study) to examine the persistence of immunity following administration of three childhood vaccines.

The efficacy of vaccine-induced immunity depends on the considerable variability in magnitude and persistence of specific antibodies. More...
Maintenance of these specific antibodies is essential for continuity of vaccine-induced serological protection.

Investigators at the University of Oxford (United Kingdom) conducted a genome-wide association study into the persistence of immunity to three childhood vaccines: capsular group C meningococcal (MenC), Haemophilus influenzae type b, and tetanus toxoid (TT) vaccines. Working with genetic data collected from 3,602 children in the United Kingdom and The Netherlands, the investigators analyzed approximately 6.7 million genetic variants affecting single nucleotide polymorphisms (SNPs) associated with vaccine-induced antibody levels.

Following analysis of the results, the investigators published detailed associations between variants in a locus containing a family of signal-regulatory proteins and the persistence of MenC immunity.

"Evoking robust and sustained vaccine-induced immunity from early life is a crucial component of global health initiatives to combat the burden of infectious disease," said first author Dr. Daniel O'Connor, postdoctoral researcher in pediatrics at the University of Oxford. "The mechanisms underlying the persistence of antibody are of major interest, since effectiveness and acceptability of vaccines would be improved if protection were sustained after infant immunization without the need for repeated boosting through childhood."

The vaccine study was published in the June 11, 2019, online edition of the journal Cell Reports.

Related Links:
University of Oxford


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.